gilteritinib FLT3
Selected indexed studies
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. (J Clin Oncol, 2024) [PMID:38277619]
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. (N Engl J Med, 2019) [PMID:31665578]
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. (J Clin Oncol, 2024) [PMID:38471061]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. (2024) pubmed
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. (2019) pubmed
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. (2024) pubmed
- Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. (2025) pubmed
- Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. (2022) pubmed
- Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. (2022) pubmed
- Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. (2022) pubmed
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. (2017) pubmed
- Gilteritinib: potent targeting of FLT3 mutations in AML. (2020) pubmed
- Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3(mut) acute myeloid leukemia. (2024) pubmed